Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can focused electrical fields deep in the brain ease Parkinson's tremors?

NCT ID NCT07827456

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 18, 2026 · Last updated Sep 18, 2026

Summary

Researchers at Tongji Hospital are testing a non-invasive brain stimulation technique called transcranial temporal interference stimulation (tTIS) in 26 people with Parkinson's disease. The study uses MRI scans to customize electrode placement so the stimulation reaches deep brain regions involved in movement. Participants receive stimulation targeting either the globus pallidus alone or combined with the subthalamic nucleus, and researchers measure motor symptom changes using a standard Parkinson's rating scale.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
MRI-guided transcranial temporal interference electrical stimulation targeting the subthalamic nucleus and globus pallidus
What this could lead to
If it works, this could offer a non-invasive way to ease Parkinson's motor symptoms without surgery or implanted electrodes.
What could go wrong
This is a small, exploratory study of 26 people, so any benefit may not hold up in larger trials or apply to all Parkinson's patients. The stimulation may cause discomfort or fail to reach deep brain targets effectively.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 26 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18-75 years (inclusive), any gender. * Diagnosis of idiopathic Parkinson's disease according to the Chinese diagnostic criteria for Parkinson's disease (2016 edition). * Hoehn and Yahr stage 2-4 (inclusive) during the "off" state. * Documented response to levodopa (\>33% improvement), with a stable anti-parkinsonian medication regimen for at least 4 weeks prior to screening, and no dose adjustments during the study. * Voluntary signed informed consent, and ability to understand and comply with the study protocol to complete the study. * No significant cognitive impairment (Montreal Cognitive Assessment \[MoCA\] score ≥21). Exclusion Criteria: Inability or unwillingness to comply with the study protocol and/or inability to provide written informed consent; Presence of a significant medical condition that may interfere with study procedures or confound the assessment of study endpoints; Presence of a severe psychiatric disorder that may affect the participant's ability to comply with the study protocol; A history of psychiatric disorders or current severe depression or anxiety; Presence of metallic implants in the brain; Known pregnancy or current breastfeeding; Severe neurological disorders, such as a brain tumor; Severe cardiac disease, including the presence of an implanted cardiac pacemaker; Scalp lesions, inflammation, infection, active bleeding, or an increased bleeding tendency; Any other current medical condition for which the use of transcranial electrical stimulation may pose an unacceptable risk; A history of epilepsy or structural brain lesions, including severe cerebral atrophy or cerebrovascular disease; Inability to undergo magnetic resonance imaging (MRI), such as because of claustrophobia or implanted metallic devices; Inability to cooperate with or complete the required assessments; or any other condition that, in the investigator's judgment, makes the individual unsuitable for participation in the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Parkinson disease (PD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.